- €14.52m
- €10.72m
- €13.19m
NASDAQ RESUMED AT 02:45 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:40 PM
NASDAQ RESUMED AT 02:35 PM
Brief: Biofrontera AG Says Decides To Delist ADS From Nasdaq To Reduce Complexity And Costs
NASDAQ TRADE HALT HALT NEWS PENDING AT 02:00 PM
Brief: Biofrontera Announces Progress Of Phase III Study For Treatment Of Sbcc With Ameluz®
Brief: Biofrontera Q4 Preliminary Revenue Between EUR 10.2 Mln And EUR 10.4 Mln
Brief: Biofrontera Announces Reduction Of Shareholding In Biofrontera Inc.
Brief: Biofrontera Announces Results Of Election To New Supervisory Board
Brief: Biofrontera Enrolls First Patient To Phase IIb Clinical Study Evaluating Ameluz® / Bf-Rhodoled®
Brief: Biofrontera Obtains Notice Of Allowance For US Patent On Pdt-Lamp And Treatment Method
Brief: Biofrontera Obtains Notice Of Allowance For U.S. Patent On Innovative Illumination Protocol
Brief: Biofrontera CEO To Leave His Post On December 13, 2021
Brief: Sun Pharma Says Its Unit DUSA Pharmaceuticals Reached Settlement With Biofrontera
Brief: Biofrontera Says Its US Subsidiary Announces $15 Mln Private Placement
Brief: Biofrontera Reaches Out-Of-Court Settlement With DUSA Pharmaceuticals
Brief: Biofrontera Says It Agrees With Deutsche Balaton On Supervisory Board Candidates
Brief: Biofrontera AG Sees FY Revenue EUR 25 Mln To EUR 32 Mln
Brief: Biofrontera AG Generated Total Sales Of EUR 18.5 Million In Period January 1 To September 30, 2021